B
Borong Zhou
Researcher at Guangzhou Medical University
Publications - 16
Citations - 1065
Borong Zhou is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 8, co-authored 9 publications receiving 446 citations.
Papers
More filters
Journal ArticleDOI
Ferroptosis is a type of autophagy-dependent cell death.
TL;DR: Current knowledge on the signaling pathways involved in ferroptosis is summarized, while focusing on the regulation of autophagy-dependent ferroptic cell death, which may lead to the development of novel anticancer therapies.
Journal ArticleDOI
The release and activity of HMGB1 in ferroptosis
TL;DR: It is demonstrated that HMGB1 is a DAMP released by ferroptotic cells in an autophagy-dependent manner, and studies suggest thatHMGB1 inhibition might have some potential therapeutic effects in ferroPTosis-associated human disease.
Journal ArticleDOI
TMEM173 Drives Lethal Coagulation in Sepsis
Hui Zhang,Ling Zeng,Min Xie,Jiao Liu,Borong Zhou,Runliu Wu,Lizhi Cao,Guido Kroemer,Haichao Wang,Timothy R. Billiar,Herbert J. Zeh,Rui Kang,Jianxin Jiang,Yan Yu,Daolin Tang,Daolin Tang +15 more
TL;DR: The upregulation of the TMEM173 pathway correlates with the severity of disseminated intravascular coagulation and mortality in patients with sepsis and is a key regulator of blood clotting during lethal bacterial infections.
Journal ArticleDOI
A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.
Rui Kang,Ling Zeng,Yangchun Xie,Zhengwen Yan,Borong Zhou,Lizhi Cao,Daniel J. Klionsky,Kevin J. Tracey,Jianhua Li,Haichao Wang,Timothy R. Billiar,Jianxin Jiang,Daolin Tang +12 more
TL;DR: An impaired PINK1-PARK2-mediated neuroimmunology pathway contributes to septic death and may represent a novel therapeutic target in critical care medicine.
Journal ArticleDOI
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
Jin Huang,Pan Chen,Ke Liu,Jiao Liu,Borong Zhou,Runliu Wu,Qiu Peng,Zexian Liu,Changfeng Li,Guido Kroemer,Michael T. Lotze,Herbert J. Zeh,Rui Kang,Daolin Tang +13 more
TL;DR: CDK1/2/5 inhibition by dinaciclib provides a novel strategy to overcome IFNG-triggered acquired resistance in pancreatic tumour immunity.